Emergent biosolution stock.

Dec 1, 2023 · Emergent BioSolutions stock has received a consensus rating of buy. The average rating score is and is based on 5 buy ratings, 3 hold ratings, and 1 sell ratings. What was the 52-week low for ... Emergent BioSolutions Stock Forecast. Is Emergent BioSolutions Stock Undervalued? The current Emergent BioSolutions [ EBS] share price is $2.09. The Score for EBS is 37, which is 26% below its historic median score of 50, and infers higher risk than normal. EBS is currently trading in the 30-40% percentile range relative to its historical Stock ...Emergent BioSolutions stock price, live market quote, shares value, historical data, intraday chart, earnings per share and news.By Will Feuer . Shares of Emergent BioSolutions Inc. rose after the U.S. Food and Drug Administration said the company's overdose reversal medication Narcan could be sold over-the-counter for the first time since the opioid crisis began.Emergent Biosolutions Inc. analyst ratings, historical stock prices, ... Actuals & Estimates Emergent Biosolutions Inc. Quarterly; Annual; Actual Analyst Range Consensus. 2.00 0.00-2.00. Actual-0.31 .

On average, analysts give Emergent Biosolutions Inc a Hold rating. The average price target is $28.4, which means analysts expect the stock to climb by 231.00% over the next twelve months. That average ranking earns Emergent Biosolutions Inc an Analyst Rating of 3, which is better than 3% of stocks based on data compiled by InvestorsObserver.

Emergent Biosolutions Inc. historical stock charts and prices, analyst ratings, financials, and today’s real-time EBS stock price. The stock of Emergent Biosolutions Inc (EBS) has seen a -5.48% decrease in the past week, with a -0.75% drop in the past month, and a -51.23% fall in the past quarter. The volatility ratio for the week is 6.73%, and the volatility levels for the past 30 days are at 9.69% for EBS. The simple moving average for the last 20 days is -6.54% for …

146.71. +1.95%. 40.54M. View today's Emergent Biosolutions Inc stock price and latest EBS news and analysis. Create real-time notifications to follow any changes in the live stock price.Emergent BioSolutions, which Mr. El-Hibri took public in 2006, bought up competitors in order to sell treatments for smallpox, botulism and other potential agents of germ warfare, becoming a prime ...The Investor Relations website contains information about Emergent BioSolutions Inc.'s business for stockholders, potential investors, and financial analysts. Skip to main navigation ... and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date ...Emergent BioSolutions ( EBS) has been quite the up-and-down stock of late. On Monday, it had an up session on the market, creeping northward by 1.2% and exceeding the S&P 500 's gain of 0.3% ...

GAITHERSBURG, Md., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced …

EBS Price Action: Emergent Biosolutions shares initially traded above $2.30 per share before pulling back. The stock was down 4.36% at $1.98 at the time of …

Emergent Biosolutions Inc. analyst ratings, historical stock prices, earnings estimates & actuals. EBS updated stock price target summary.NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shown.Our Mission. At Emergent, we develop, manufacture, and deliver protections against public health threats through a pipeline of innovative vaccines and therapeutics worldwide. For 25 years, we’ve been at work defending people from things we hope will never happen—so that we’re prepared, just in case they ever do.EBS Price Action: Emergent Biosolutions has a 52-week high of $45.02 and a 52-week low of $7.74. The stock was up 18.9% at $10.59 at time of publication, according to Benzinga Pro. Photo: courtesy ...According to the issued ratings of 2 analysts in the last year, the consensus rating for Emergent BioSolutions stock is Reduce based on the current 1 sell rating and 1 hold rating for EBS. The average twelve-month price prediction for Emergent BioSolutions is $15.50 with a high price target of $22.00 and a low price target of $9.00.

Why Emergent BioSolutions Stock Is Sinking Today (Motley Fool)-15.85%. Mar-10-23 06:56AM Emergent BioSolutions Inc. (NYSE:EBS) Q4 2022 Earnings Call Transcript (Insider Monkey) Mar-01-23 05:32AM Emergent BioSolutions Full Year 2022 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall ...Emergent BioSolutions stock price, live market quote, shares value, historical data, intraday chart, earnings per share and news.Revenue Metrics. Total revenues for 2022 are expected to be in the range of $1,100 million to $1,120 million, a decrease at the midpoint of $683 million or 38% as compared to 2021. Profitability ...The company’s stock price dipped and shareholders sued Emergent, claiming they had been misled. ... Emergent Biosolutions, is having with the lack of clarity and transparency in CDC's ...Nov 4, 2021 · Emergent BioSolutions ruined millions of doses of Covid-19 vaccines. Now its $600 million deal is canceled. Share full article. One of Emergent BioSolutions’ plants in Baltimore last April. Shares of Emergent Biosolutions ( EBS -0.47%) have crashed 41.1% as of 11:44 a.m. EDT on Friday. The huge decline came after the company revealed on Thursday that a multimillion-dollar agreement ...GAITHERSBURG, Md., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the fourth quarter and year ended December 31, 2021. "Emergent’s performance in 2021 is a testament to our strategic focus and highly capable team," said Robert G. Kramer, president and CEO of Emergent …

Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola. 07/25/23. Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023. 07/20/23.

Shares of Emergent BioSolutions ( EBS 11.68%) were tumbling 10.6% lower as of 11:29 a.m. ET on Tuesday. The decline came after S&P Global 's S&P Dow Jones Indices announced that Advance Auto Parts ...Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. [2] It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. Emergent BioSolutions Inc. Stock , EBS 2.39 + +% After-market 06:53:01 PM EDT 12/1/2023 NYSE Add to watchlist 2.39 +0.25 +11.68% Official Close 04:00:00 …A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 ...Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -8.16% and 59.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?Shares of Emergent Biosolutions ( EBS -0.47%) have crashed 41.1% as of 11:44 a.m. EDT on Friday. The huge decline came after the company revealed on Thursday that a multimillion-dollar agreement ...Emergent BioSolutions. GAITHERSBURG, Md., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced a sharpened strategic focus on protecting and enhancing life through ...Is Emergent Biosolutions Inc stock A Buy? Several short-term signals are positive, despite the stock being in a falling trend, we conclude that the current ...

See the latest Emergent BioSolutions Inc stock price (EBS:XNYS), related news, valuation, dividends and more to help you make your investing decisions.

A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 ...

Tasos Katopodis. Contract manufacturer Emergent BioSolutions ( NYSE: EBS) fell ~3% in early pre-market trading Thursday after announcing its plans to sell $150M shares of common stock under an ...Nov 7, 2013 · A high-level overview of Emergent BioSolutions Inc. (EBS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Shares of Emergent Biosolutions ( EBS -0.47%) have crashed 41.1% as of 11:44 a.m. EDT on Friday. The huge decline came after the company revealed on Thursday that a multimillion-dollar agreement ...Emergent BioSolutions Inc EBS Morningstar Rating Unlock Stock XNYS Rating as of Nov 29, 2023 Summary Chart News Price vs Fair Value Sustainability …Emergent Biosolutions Inc Stock Price History. Emergent Biosolutions Inc’s price is currently down 37.08% so far this month. During the month of March, Emergent Biosolutions Inc’s stock price has reached a high of $12.54 and a low of $7.77. Over the last year, Emergent Biosolutions Inc has hit prices as high as $45.14 and as …Emergent Biosolutions, Inc. Common Stock (EBS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Emergent Biosolutions Inc. analyst ratings, historical stock prices, earnings estimates & actuals. EBS updated stock price target summary.Jul. 31, 2023, 05:14 PM. Emergent Biosolutions Inc (NYSE:EBS) shares are trading higher in Monday's after-hours session after the company was awarded a 10-year contract for development of an Ebola ...Emergent BioSolutions has seen a significant revenue decline and stock value drop within the past year. The FDA has approved Emergent's over-the-counter Narcan, a drug to treat opioid overdoses.Historical daily share price chart and data for Emergent Biosolutions since 2006 adjusted for splits and dividends. The latest closing stock price for ...

See the latest Emergent BioSolutions Inc stock price (EBS:XNYS), related news, valuation, dividends and more to help you make your investing decisions.Institutions' substantial holdings in Emergent BioSolutions implies that they have significant influence over the company's share price 50% of the business is held by the top 15 shareholdersEmergent Biosolutions Inc. analyst ratings, historical stock prices, ... Actuals & Estimates Emergent Biosolutions Inc. Quarterly; Annual; Actual Analyst Range Consensus. 2.00 0.00-2.00. Actual-0.31 .Instagram:https://instagram. how to trade spy options dailyetf for restaurantshow to analyze reitsinsurance for outside water pipes N/A. N/A. See Emergent BioSolutions Inc. (EBS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.Emergent Biosolutions Inc Stock Price History. Emergent Biosolutions Inc’s price is currently up 19.5% so far this month. During the month of April, Emergent Biosolutions Inc’s stock price has reached a high of $12.56 and a low of $9.47. Over the last year, Emergent Biosolutions Inc has hit prices as high as $43.46 and as low as $7.74. brokers that work with metatrader 5best ivf insurance Oct 9, 2023 · NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits and/or dividends which may have occurred for this security since the date shown. The Split Adjustment Factor is a cumulative factor which encapsulates all splits since the date shown. See the latest Emergent BioSolutions Inc stock price (EBS:XNYS), related news, valuation, dividends and more to help you make your investing decisions. list of stock symbols View printer-friendly version. Emergent BioSolutions Statement on Generic Version of NARCAN® Nasal Spray. GAITHERSBURG, Md. – Based on publicly available information, it appears that Teva Pharmaceutical Industries Ltd. has launched a generic naloxone nasal spray, prior to resolution of the related pending patent litigation. “Emergent is proud of …Emergent Biosolutions is part of the Zacks Medical - Biomedical and Genetics industry. Rapt Therapeutics RAPT, another stock in the same industry, closed the last trading session 2.7% higher at ...